TWIST1 and breast cancer: Nayak et al. reported that IKM5 (2-(1-(1H-indol-3-yl)octyl)-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one), a novel indolylkojyl methane analogue, inhibits EMT and invasion in breast cancer cells by binding to GRP78 and decreasing its expression along with the downregulation of EMT markers, such as vimentin, Twist1, and MMP2 [221].